GSK wins FDA approval for lung cancer drug Nelkarmi

GSK received FDA approval for its lung cancer drug Nelkarmi, targeting ALK gene mutations. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts estimate $1B in 2032 sales. GSK aims to expand its oncology portfolio under CEO Luke Miels.

Original reporting
Published Nov 17, 2026, 6:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 6:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$GSK
Bullish
high confidence
Mentioned
$GSK
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

This is a regulatory milestone that reduces clinical and approval risk for GSK’s ALK-mutant NSCLC program, but the article flags that confirmatory late-stage benefits are still pending.

02

Market read

Traders may reassess GSK’s oncology pipeline quality and near-term commercialization expectations following a new FDA approval tied to a recent acquisition.

03

What to watch

Commercial traction will depend on sequencing versus existing ALK therapies, payer coverage decisions, and results from the ongoing late-stage study that could confirm or dilute the early-stage benefit.

Relevance 7/10Novelty 8/10Timing: FDA approval reported today, before/around the next trading session

Background

GSK’s FDA approval for neladalkib (Nelkarmi) follows its $10.6B Nuvalent acquisition, which also delivered another approved drug (Jideytro).

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

GSK received FDA approval for its lung cancer drug Nelkarmi (neladalkib), validating its Nuvalent acquisition and expanding its oncology pipeline.

Expected impact

Likely upward bias as the market prices in commercialization optionality and reduced regulatory risk, tempered by uncertainty around full late-stage benefit.

Evidence & confidence

The article reports a new FDA approval and links it directly to GSK’s Nuvalent acquisition, which is a concrete, decision-grade catalyst; it also notes an ongoing late-stage study, limiting certainty on ultimate efficacy and uptake.

Market effects

Strengthens the ALK-driven lung cancer competitive set and highlights continued value creation from oncology M&A and accelerated approvals.

Supports UK pharma sentiment via a US regulatory milestone.

US FDA approvals can re-rate global pharma oncology pipelines and influence peer expectations for ALK-targeted development.

Counterpoint

Accelerated approval may not translate into durable label expansion or strong uptake if confirmatory trials underperform or if safety/tolerability limits adoption versus existing ALK drugs.

Key entities

  • GSK

    Received FDA approval for Nelkarmi (neladalkib) for ALK-driven non-small cell lung cancer.

  • Nuvalent

    Biotechnology acquired by GSK; its rights underpin the Nelkarmi approval.

  • FDA

    Granted accelerated approval for the specified NSCLC indication.

Related articles

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.

$GSKHigh

GSK Wins Early FDA Nod for Nelkarmi

GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.